Valion Bio Inc (VBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Valion Bio Inc (VBIO) has a cash flow conversion efficiency ratio of -0.136x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.29 Million) by net assets ($16.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Valion Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Valion Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Valion Bio Inc debt and liabilities for a breakdown of total debt and financial obligations.
Valion Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valion Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Evergold Corp
V:EVER
|
-0.286x |
|
Zeta Network Group
NASDAQ:ZNB
|
-0.282x |
|
FAT Brands Inc
NASDAQ:FAT
|
0.024x |
|
Apex Resources Inc
V:APX
|
-0.058x |
|
Capricorn Energy PLC
LSE:CNE
|
0.335x |
|
SpectraCure AB
ST:SPEC
|
-0.048x |
|
Abits Group Inc.
NASDAQ:ABTS
|
0.255x |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
-1.214x |
Annual Cash Flow Conversion Efficiency for Valion Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Valion Bio Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Valion Bio Inc (VBIO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-7.00 Million | -0.417x | +81.55% |
| 2024-12-31 | $2.54 Million | $-5.72 Million | -2.258x | +5.01% |
| 2023-12-31 | $3.58 Million | $-8.51 Million | -2.377x | +3.24% |
| 2022-12-31 | $3.63 Million | $-8.92 Million | -2.457x | -32.17% |
| 2020-12-31 | $863.39K | $-1.61 Million | -1.859x | +33.60% |
| 2019-12-31 | $1.28 Million | $-3.59 Million | -2.800x | +68.74% |
| 2017-12-31 | $322.27K | $-2.89 Million | -8.957x | -- |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more